ValeurQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMFrais de vente, généraux et administratifs1.61 B1.6 B1.72 B1.74 B1.83 B1.78 B7.07 BRecherche et développement459 M443 M526 M514 M569 M516 M2.13 BRésultat d'exploitation675 M921 M819 M1.05 B825 M1.1 B3.79 BTotal des produits hors exploitation-115 M-144 M341 M-120 M-173 M219 M267 MCharges d'intérêts, nettes des intérêts capitalisés80 M82 M90 M87 M90 M90 M357 MRésultat hors exploitation, hors charges d'intérêts-106 M-110 M129 M-97 M-139 M68 M-39 MRevenus/dépenses exceptionnels-89 M-116 M122 M-110 M-124 M61 M-51 MRésultat avant impôts585 M805 M941 M939 M700 M1.16 B3.74 BPart des actionnaires dans le résultat———————Impôts23 M133 M146 M183 M31 M-176 M184 MIntérêts ne donnant pas le contrôle / intérêts minoritaires-5 M-2 M-2 M0-2 M-2 M-6 MAutres produits/charges après impôts———————Résultat net avant activités abandonnées563 M672 M795 M755 M670 M1.34 B3.56 BActivités abandonnées———————Résultat net563 M672 M795 M755 M670 M1.34 B3.56 BAjustement de dilution———————Dividendes privilégiés———————Résultat net dilué revenant aux actionnaires ordinaires565 M674 M797 M755 M672 M1.34 B3.56 BBénéfice par action de base (BPA de base)0.380.460.540.510.450.92.4Bénéfice par action dilué (BPA dilué)0.380.450.530.510.450.92.39Nombre moyen d'actions de base en circulation1.47 B1.48 B1.48 B1.48 B1.48 B1.48 B—Nombre d'actions en circulation après dilution1.49 B1.49 B1.49 B1.5 B1.49 B1.5 B—EBITDA1.02 B1.25 B1.16 B1.39 B1.19 B1.45 B5.18 BEBIT676 M922 M819 M1.05 B823 M1.1 B3.79 BCoût des ventes1.47 B1.45 B1.64 B1.52 B1.61 B1.59 B6.36 BAutres coûts des ventes———————Amortissements (flux de trésorerie)348 M325 M336 M342 M365 M351 M1.39 B
Boston Scientific Corporation Common Stock
Boston Scientific Corporation is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
The company is known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. The company acquired Cameron Health in June 2012 and began to offer a minimally invasive implantable cardioverter-defibrillator called the EMBLEM subcutaneous implantable defibrillator.
Over the last 20 years, Boston Scientific has had some high-profile patent infringement cases. It has made extensive payouts, including $1.725 billion to Johnson & Johnson, $85 million to Nevro and $42 million to TissueGen.
BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware.